Epilepsy trials in Australia

In Australia 22 Also abroad 452

22 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Where
Heidelberg, Melbourne, Nedlands, South Brisbane
Age
4 years to 55 years
People
252 worldwide
Run by
SK Life Science, Inc.
See details and how to joinNCT05219617
Phase 3Taking people
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Where
Melbourne, Sydney
Age
18 years to 75 years
People
333 worldwide
Run by
Rapport Therapeutics Inc.
See details and how to joinNCT07563881
Phase 3Taking people
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Where
Melbourne
Age
18 years to 75 years
People
312 worldwide
Run by
Rapport Therapeutics Inc.
See details and how to joinNCT07594119
Phase 3Taking people
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Where
Heidelberg, Kogarah, Melbourne, Parkville, South Brisbane
Age
12 years and over
People
160 worldwide
Run by
Xenon Pharmaceuticals Inc.
See details and how to joinNCT05667142 · EU 2022-502286-16-00
Phase 3Taking people
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Where
Camperdown, Melbourne, Randwick, Westmead
Age
18 years and over
People
360 worldwide
Run by
Xenon Pharmaceuticals Inc.
See details and how to joinNCT05716100 · EU 2022-502281-25-00
Phase 3Enrolling by invitation
An Open-label Study of XEN1101 in Epilepsy
Where
Camperdown, Fitzroy, Heidelberg, Kogarah, Melbourne, Parkville, Randwick, South Brisbane, Westmead
Age
12 years and over
People
880 worldwide
Run by
Xenon Pharmaceuticals Inc.
See details and how to joinNCT05718817 · EU 2022-502282-24-00
Phase 2Enrolling by invitation
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
Where
Melbourne
Age
18 years and over
People
100 worldwide
Run by
Supernus Pharmaceuticals, Inc.
See details and how to joinNCT07141329 · EU 2026-526361-15-00
Phase 1/2Taking people
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Where
Melbourne
Age
6 months to 17 years
People
113 worldwide
Run by
Encoded Therapeutics
See details and how to joinNCT05419492
No phaseTaking people
Artificial Intelligence for Brain MRI Analysis in Epilepsy
Where
Melbourne
People
2,000 worldwide
Run by
Istituto Giannina Gaslini
See details and how to joinNCT07881185
Phase 3Enrolling by invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
Where
Brisbane, Heidelberg, Parkville, Randwick, Westmead
Age
2 years to 66 years
People
324 worldwide
Run by
Longboard Pharmaceuticals
See details and how to joinNCT06908226 · EU 2024-514974-39-00
Phase 2Taking people
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Where
Adelaide, Clayton, Fitzroy, Herston, Melbourne, Nedlands, Parkville
Age
18 years to 70 years
People
216 worldwide
Run by
Supernus Pharmaceuticals, Inc.
See details and how to joinNCT06798896
Phase 2Taking people
A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy
Where
Melbourne
Age
18 years to 70 years
People
180
Run by
Shanghai Zhimeng Biopharma, Inc.
See details and how to joinNCT06612775
No phaseTaking people
Feasibility Study of the iVEAcare Neuromodulation System for the Treatment of Drug-Resistant Epilepsy
Where
Clayton, Fitzroy, Heidelberg, Herston, Melbourne, Parkville, South Brisbane
Age
4 years to 75 years
People
30
Run by
iVEAcare
See details and how to joinNCT07640191
No phaseTaking people
Prospective Natural History Study of POLG Disease
Where
Sydney
People
300 worldwide
Run by
The POLG Foundation
See details and how to joinNCT07775872
No phaseTaking people
Evaluation of the NaviFUS System in Drug Resistant Epilepsy
Where
Melbourne
Age
18 years and over
People
18
Run by
Genovate-NaviFUS (Australia) Pty Ltd.
See details and how to joinNCT05947656
No phaseNot yet taking people in Australia
IBIS - Investigating Reliability of BIS and SEDLINE Monitoring in Children With Developmental and Epileptic Encephalopathies (DEE).
Where
Perth
Age
0 years to 15 years
People
40 worldwide
Run by
Telethon Kids Institute
See details and how to joinNCT07585643
No phaseEnrolling by invitation
5-SENSE Score Validation Study
Where
Brisbane, Melbourne
Age
15 years and over
People
400 worldwide
Run by
Duke University
See details and how to joinNCT06138808
Phase 2Enrolling by invitation
Long-term Safety and Tolerability of BHV-7000
Where
Bedford Park, Camperdown, Fitzroy, Heidelberg, Herston, Melbourne, Parkville, Randwick
Age
18 years to 75 years
People
660 worldwide
Run by
Biohaven Therapeutics Ltd.
See details and how to joinNCT06443463 · EU 2023-508813-18-00
Phase 2Taking people
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
Where
Box Hill, Brisbane, Heidelberg, Melbourne, Parkville, Randwick, Sydney
Age
18 years to 70 years
People
60 worldwide
Run by
Supernus Pharmaceuticals, Inc.
See details and how to joinNCT05518578
Phase 2Taking people
An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy
Where
Melbourne
Age
18 years to 70 years
People
144
Run by
Shanghai Zhimeng Biopharma, Inc.
See details and how to joinNCT07238868
Phase 2Taking people
BMB-101 in Absence Epilepsy and DEE
Where
Fitzroy, Heidelberg, Herston, Melbourne, Randwick
Age
18 years to 65 years
People
20
Run by
Bright Minds Biosciences Pty Ltd
See details and how to joinNCT06401538
Phase 2Taking people
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
Where
Heidelberg, Melbourne
Age
18 years to 75 years
People
50 worldwide
Run by
Praxis Precision Medicines
See details and how to joinNCT06908356